Matuzumab plus epirubicin, cisplatin and capecitabine (ECX) compared with epirubicin, cisplatin and capecitabine alone as first-line treatment in patients with advanced oesophago-gastric cancer: A randomised, multicentre open-label phase II study

Annals of Oncology

Volumn 21, Issue 11, 2010, Pages 2213-2219

  Rao, S ^a   Starling, N ^a   Cunningham, D ^a   Sumpter, K ^b   Gilligan, D ^c   Ruhstaller, T ^d   Valladares Ayerbes, M ^e   Wilke, H ^f   Archer, C ^g   Kurek, R ^h   Beadman, C ^h   Oates, J ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b NEWCASTLE GENERAL HOSPITAL   (United Kingdom)

^c CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^d Department of Haematology and Oncology ^*  (Switzerland)

^e HOSPITAL JUAN CANALEJO   (Spain)

^f KLINIKEN ESSEN MITTE   (Germany)

^g ST MARY S HOSPITAL   (United Kingdom)

^h Merck Serono GmbH   (Germany)

Author keywords

Advanced; Anti EGFR; Chemotherapy; Oesophago gastric cancer; Randomised; Treatment

Indexed keywords

CAPECITABINE; CISPLATIN; EPIRUBICIN; MATUZUMAB;

ADULT; AGED; ANEMIA; ARTICLE; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEHYDRATION; DIARRHEA; DRUG EFFICACY; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; ESOPHAGOGASTRIC CANCER; ESOPHAGUS CANCER; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HAND FOOT SYNDROME; HEART INFARCTION; HUMAN; HYPERKALEMIA; HYPOKALEMIA; INFECTION; LETHARGY; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OPEN STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SENSORY NEUROPATHY; SKIN DISEASE; STOMACH CANCER; SURVIVAL TIME; SYNCOPE; THROMBOCYTOPENIA;

EID: 77958496605     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq247     Document Type: Article

References (37)

1. Parkin DM. Global cancer statistics in the year 2000. Lancet Oncol 2001; 2: 533-543.
2. Pyrhonen S, Kuitunen T, Nyandoto P et al. Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer 1995; 71: 587-591.
3. Murad AM, Santiago FF, Petroianu A et al. Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer 1993; 72: 37-41.
4. Webb A, Cunningham D, Scarffe JH et al. Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol 1997; 15: 261-267.
5. Ross P, Nicolson M, Cunningham D et al. Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) with epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer. J Clin Oncol 2002; 20: 1996-2004.
6. Wagner AD, Grothe W, Haerting J et al. Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol 2006; 24: 2903-2909.
7. Sumpter K, Harper-Wynne C, Cunningham D et al. Report of two protocol planned interim analyses in a randomised multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric cancer receiving ECF. Br J Cancer 2005; 92: 1976-1983.
8. Borner MM, Schoffski P, de Wit R et al. Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer. Eur J Cancer 2002; 38: 349-358.
9. Hoff PM, Ansari R, Batist G et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol 2001; 19: 2282-2292.
10. Liu G, Franssen E, Fitch MI et al. Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol 1997; 15: 110-115.
11. Cunningham D, Starling N, Rao S et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 2008; 358: 36-46.
12. Van Cutsem E, Moiseyenko VM, Tjulandin S et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 2006; 24: 4991-4997.
13. Dank M, Zaluski J, Barone C et al. Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction. Ann Oncol 2008; 19: 1450-1457.
14. Kim H, Muller WJ. The role of the epidermal growth factor receptor family in mammary tumorigenesis and metastasis. Exp Cell Res 1999; 253: 78-87.
15. Olayioye MA, Beuvink I, Horsch K et al. ErbB receptor-induced activation of stat transcription factors is mediated by Src tyrosine kinases. J Biol Chem 1999; 274: 17209-17218.
16. Sako Y, Minoghchi S, Yanagida T. Single-molecule imaging of EGFR signalling on the surface of living cells. Nat Cell Biol 2000; 2: 168-172.
17. Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 2000; 103: 211-225.
18. Hirono Y, Tsugawa K, Fushida S et al. Amplification of epidermal growth factor receptor gene and its relationship to survival in human gastric cancer. Oncology 1995; 52: 182-188.
19. Yonemura Y, Sugiyama K, Fujimura T et al. Epidermal growth factor receptor status and S-phase fractions in gastric carcinoma. Oncology 1989; 46: 158-161.
20. Itakura Y, Sasano H, Shiga C et al. Epidermal growth factor receptor overexpression in esophageal carcinoma. An immunohistochemical study correlated with clinicopathologic findings and DNA amplification. Cancer 1994; 74: 795-804.
21. Shimada Y, Imamura M, Watanabe G et al. Prognostic factors of oesophageal squamous cell carcinoma from the perspective of molecular biology. Br J Cancer 1999; 80: 1281-1288.
22. Rao S, Starling N, Cunningham D et al. Phase I study of epirubicin, cisplatin and capecitabine plus matuzumab in previously untreated patients with advanced oesophagogastric cancer. Br J Cancer 2008; 99(6): 868-874.
23. Vanhoefer U, Tewes M, Rojo F et al. Phase I study of the humanized antiepidermal growth factor receptor monoclonal antibody EMD72000 in patients with advanced solid tumors that express the epidermal growth factor receptor. J Clin Oncol 2004; 22: 175-184.
24. Wolf M, Swaisland H, Averbuch S. Development of the novel biologically targeted anticancer agent gefitinib: determining the optimum dose for clinical efficacy. Clin Cancer Res 2004; 10: 4607-4613.
25. Segaert S, Van Cutsem E. Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann Oncol 2005; 16: 1425-1433.
26. Lenz HJ. Anti-EGFR mechanism of action: antitumor effect and underlying cause of adverse events. Oncology (Williston Park) 2006; 20: 5-13.
27. Graeven U, Kremer B, Sudhoff T et al. Phase I study of the humanised anti-EGFR monoclonal antibody matuzumab (EMD 72000) combined with gemcitabine in advanced pancreatic cancer. Br J Cancer 2006; 94: 1293-1299.
28. Kollmannsberger C, Schittenhelm M, Honecker F et al. A phase I study of the humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody EMD 72000 (matuzumab) in combination with paclitaxel in patients with EGFR-positive advanced non-small-cell lung cancer (NSCLC). Ann Oncol 2006; 17: 1007-1013.
29. Schrag D, Chung KY, Flombaum C et al. Cetuximab therapy and symptomatic hypomagnesemia. J Natl Cancer Inst 2005; 97: 1221-1224.
30. Fakih MG, Wilding G, Lombardo J. Cetuximab-induced hypomagnesemia in patients with colorectal cancer. Clin Colorectal Cancer 2006; 6: 152-156.
31. Funaioli C, Pinto C, De Fabio F et al. Evaluation of electrolytic imbalance in patients with advanced colorectal and gastric cancer treated with anti-EGFR monoclonal antibody-based therapy. In American Society Of Clinical Oncology Annual Meeting (Vol. May 20 Suppl), 2008.
32. Zhang X, Xu J, Shen L et al. A phase II study of cetuximab (Cetuximab) with cisplatin and capecitabine (Xeloda) as 1st line treatment in advanced gastric cancer. In American Society of Clinical Oncology Annual Meeting (Vol. May 20 Suppl), 2008.
33. Han S, Park SR, Lee K et al. Phase II study and biomarker analysis of cetuximab in combination with oxaliplatin, 5-fluorouracil, leucovorin as first-line treatment in patients with recurrent or metastatic gastric cancer. In American Society of Clincal Oncology Annual Meeting (Vol. May 20 Suppl), 2008.
34. Moehler MH, Trarbach T, Seufferlein T et al. Cetuximab with irinotecan/Na-Fa/5-FU as first-line treatment in advanced gastric cancer: preliminary results of a nonrandomised multi-centre AIO phase II study. In Gastrointestinal Cancers Symposium, 2008.
35. Pinto C, Di Fabio F, Siena S et al. Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study). Ann Oncol 2007; 18: 510-517.
36. Dragovich T, McCoy S, Fenoglio-Preiser CM et al. Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127. J Clin Oncol 2006; 24: 4922-4927.
37. Van Cutsem E, Kang Y, Chung H et al. Efficacy results from the ToGA trial: a phase III study of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (GC), American Society of Clinical Oncology Annual Meeting. Journal of Clincal Oncology 2009; (18S).